MENU
+Compare
INMB
Stock ticker: NASDAQ
AS OF
Apr 10, 01:48 PM (EDT)
Price
$6.85
Change
-$0.78 (-10.22%)
Capitalization
173.12M

INMB INmune Bio Forecast, Technical & Fundamental Analysis

INmune Bio Inc is a clinical-stage biotechnology company... Show more

Industry: #Biotechnology
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for INMB with price predictions
Apr 09, 2025

INMB in +5.13% Uptrend, growing for three consecutive days on March 31, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where INMB advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 61 cases where INMB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

INMB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on April 02, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on INMB as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for INMB turned negative on March 27, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

INMB moved below its 50-day moving average on March 26, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for INMB crossed bearishly below the 50-day moving average on March 19, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INMB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for INMB entered a downward trend on March 27, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. INMB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.394) is normal, around the industry mean (13.320). P/E Ratio (0.000) is within average values for comparable stocks, (62.790). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.760). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. INMB's P/S Ratio (10000.000) is very high in comparison to the industry average of (246.160).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

INMB is expected to report earnings to rise 21.25% to -48 cents per share on April 30

INmune Bio INMB Stock Earnings Reports
Q1'25
Est.
$-0.49
Q4'24
Beat
by $0.15
Q3'24
Missed
by $0.08
Q2'24
Beat
by $0.13
Q1'24
Missed
by $0.08
The last earnings report on March 27 showed earnings per share of -40 cents, beating the estimate of -55 cents. With 99.75K shares outstanding, the current market capitalization sits at 173.12M.
A.I. Advisor
published General Information

General Information

a developer of therapies that harness the patient's immune system to treat cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
225 NE Mizner Boulevard
Phone
+1 858 964-3720
Employees
17
Web
https://www.inmunebio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYVIX158.11N/A
N/A
Rydex Energy Services Inv
GIEYX13.29N/A
N/A
GuideStone Funds International Eq Instl
JIBCX49.05N/A
N/A
JHancock Blue Chip Growth 1
QASGX20.42N/A
N/A
Federated Hermes MDT Small Cap Growth A
ASQCX11.53N/A
N/A
American Century Small Company C

INMB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, INMB has been loosely correlated with ABCL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if INMB jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INMB
1D Price
Change %
INMB100%
+10.38%
ABCL - INMB
43%
Loosely correlated
+11.92%
ATOS - INMB
41%
Loosely correlated
+4.91%
MDGL - INMB
41%
Loosely correlated
+3.69%
RARE - INMB
39%
Loosely correlated
+9.18%
PRME - INMB
38%
Loosely correlated
+8.70%
More